Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals

Clinical and Translational Gastroenterology

Volumn 7, Issue 7, 2016, Pages

  Nagao, Yumiko ^a,b   Kimura, Kanae ^a   Kawahigashi, Yuji ^a   Sata, Michio ^a,b,c  

^a SAGA UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Nishinihon Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; ASUNAPREVIR; BILIRUBIN; CHOLESTEROL; DACLATASVIR; PROTEIN;

ABSENCE OF SIDE EFFECTS; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LICHEN PLANUS; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84977653296     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2016.35     Document Type: Article

References (36)

1. Global Burden Of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20-29.
2. Uemura M, Sasaki Y, Yamada T et al. Serum antibody titers against hepatitis C virus and postoperative intrahepatic recurrence of hepatocellular carcinoma. Ann Surg Oncol 2014; 21: 1719-1725.
3. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
4. Ikeda M, Mitsunaga S, Shimizu S et al. Current status of hepatocellular carcinoma in Japan. Chin Clin Oncol 2013; 2: 40.
5. Gumber SC, Chopra S. Hepatitis C: A multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123: 615-620.
6. Cacoub P, Gragnani L, Comarmond C et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014; 46 (Suppl 5): S165-S173.
7. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-965.
8. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
9. Kumada H, Suzuki Y, Ikeda K et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083-2091.
10. Omata M, Nishiguchi S, Ueno Y et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: An open-label, phase 3 trial. J Viral Hepat 2014; 21: 762-768.
11. Mizokami M, Yokosuka O, Takehara T et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: An open-label, randomised, phase 3 trial. Lancet Infect Dis 2015; 15: 645-653.
12. Nagao Y, Sata M, Tanikawa K et al. Lichen planus and hepatitis C virus in the northern Kyushu region of Japan. Eur J Clin Invest 1995; 25: 910-914.
13. Carrozzo M, Gandolfo S, Carbone M et al. Hepatitis C virus infection in Italian patients with oral lichen planus: A prospective case-control study. J Oral Pathol Med 1996; 25: 527-533.
14. Nagao Y, Sata M, Ide T et al. Development and exacerbation of oral lichen planus during and after interferon therapy for hepatitis C. Eur J Clin Invest 1996; 26: 1171-1174.
15. Nagao Y, Kawaguchi T, Ide T et al. Exacerbation of oral erosive lichen planus by combination of interferon and ribavirin therapy for chronic hepatitis C. Int J Mol Med 2005; 15: 237-241.
16. Grossmann Sde M, Teixeira R, de Aguiar MC et al. Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Eur J Gastroenterol Hepatol 2008; 20: 702-706.
17. Nagao Y, Sata M. Analysis of the factors motivating HCV-infected patients to accept interferon therapy. BMC Res Notes 2012; 5: 470.
18. Lee SC, Antony A, Lee N et al. Improved version 2. 0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol 2000; 38: 4171-4179.
19. Sizmann D, Boeck C, Boelter J et al. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2007; 38: 326-333.
20. Dusheiko G, Schmilovitz-Weiss H, Brown D et al. Hepatitis C virus genotypes: An investigation of type-specific differences in geographic origin and disease. Hepatology 1994; 19: 13-18.
21. Kawamura Y, Ikeda K, Arase Y et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007; 120: 1034-1041.
22. Arase Y, Suzuki F, Suzuki Y et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49: 739-744.
23. Arase Y, Suzuki F, Kawamura Y et al. Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. Hepatol Res 2011; 41: 946-954.
24. Arase Y, Suzuki F, Suzuki Y et al. Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus. J Med Virol 2010; 82: 390-395.
25. Arase Y, Kobayashi M, Kawamura Y et al. Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C. J Med Virol 2014; 86: 169-175.
26. Nagao Y, Sata M, Suzuki H et al. Histological improvement of oral lichen planus in patients with chronic hepatitis C treated with interferon. Gastroenterology 1999; 117: 283-284.
27. Garcovich S, Garcovich M, Capizzi R et al. Cutaneous manifestations of hepatitis C in the era of new antiviral agents. World J Hepatol 2015; 7: 2740-2748.
28. Makara M, Sulyok M, Csacsovszki O et al. Successful treatment of HCV-associated cryoglobulinemia with ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin: A case report. J Clin Virol 2015; 72: 66-68.
29. Gonzalez-Moles MA, Scully C, Gil-Montoya JA. Oral lichen planus: controversies surrounding malignant transformation. Oral Dis 2008; 14: 229-243.
30. Klosek SK, Sporny S, Stasikowska-Kanicka O et al. Cigarette smoking induces overexpression of c-Met receptor in microvessels of oral lichen planus. Arch Med Sci 2011; 7: 706-712.
31. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol 2011; 3: S7-S19.
32. Albrecht M, Banoczy J, Dinya E et al. Occurrence of oral leukoplakia and lichen planus in diabetes mellitus. J Oral Pathol Med 1992; 21: 364-366.
33. Baykal L, Arica DA, Yayli S et al. Prevalence of metabolic syndrome in patients with mucosal lichen planus: A case-control study. Am J Clin Dermatol 2015; 16: 439-445.
34. Nagao Y, Kawasaki K, Sata M. Insulin resistance and lichen planus in patients with HCVinfectious liver diseases. J Gastroenterol Hepatol 2008; 23: 580-585.
35. Nagao Y, Sata M. Oral verrucous carcinoma arising from lichen planus and esophageal squamous cell carcinoma in a patient with hepatitis C virus-related liver cirrhosishyperinsulinemia and malignant transformation: A case report. Biomed Rep 2013; 1: 53-56.
36. Nagao Y, Hashimoto K, Sata M. Candidiasis and other oral mucosal lesions during and after interferon therapy for HCV-related chronic liver diseases. BMC Gastroenterol 2012; 12: 155.